Why is ImmuCell Corp. ?
1
Weak Long Term Fundamental Strength with a 34.00% CAGR growth in Operating Profits over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -1.93
- The company has been able to generate a Return on Equity (avg) of 0.66% signifying low profitability per unit of shareholders funds
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is ImmuCell Corp. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
ImmuCell Corp.
30.55%
0.71
58.39%
S&P 500
16.12%
0.77
19.29%
Quality key factors
Factor
Value
Sales Growth (5y)
12.77%
EBIT Growth (5y)
34.00%
EBIT to Interest (avg)
-1.93
Debt to EBITDA (avg)
1.67
Net Debt to Equity (avg)
0.21
Sales to Capital Employed (avg)
0.60
Tax Ratio
4.06%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
15.05%
ROCE (avg)
0.87%
ROE (avg)
0.66%
Valuation Key Factors 
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
1.95
EV to EBIT
27.41
EV to EBITDA
12.67
EV to Capital Employed
1.80
EV to Sales
2.30
PEG Ratio
0.16
Dividend Yield
NA
ROCE (Latest)
6.56%
ROE (Latest)
7.80%
Technical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
Mildly Bearish
Technical Movement
17What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 1.99 MM
NET PROFIT(HY)
Higher at USD 0.36 MM
ROCE(HY)
Highest at 8.27%
RAW MATERIAL COST(Y)
Fallen by -65.43% (YoY
DEBT-EQUITY RATIO
(HY)
Lowest at 32.61 %
DEBTORS TURNOVER RATIO(HY)
Highest at 11.22 times
-11What is not working for the Company
PRE-TAX PROFIT(Q)
At USD -0.14 MM has Fallen at -130.52%
NET PROFIT(Q)
At USD -0.14 MM has Fallen at -131.72%
INVENTORY TURNOVER RATIO(HY)
Lowest at 1.9 times
NET SALES(Q)
Lowest at USD 5.51 MM
Here's what is working for ImmuCell Corp.
Operating Cash Flow
Highest at USD 1.99 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Debt-Equity Ratio
Lowest at 32.61 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Debtors Turnover Ratio
Highest at 11.22 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -65.43% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for ImmuCell Corp.
Net Sales
At USD 5.51 MM has Fallen at -22.11%
over average net sales of the previous four periods of USD 7.07 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (USD MM)
Pre-Tax Profit
At USD -0.14 MM has Fallen at -130.52%
over average net sales of the previous four periods of USD 0.44 MMMOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -0.14 MM has Fallen at -131.72%
over average net sales of the previous four periods of USD 0.44 MMMOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Net Sales
Lowest at USD 5.51 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (USD MM)
Inventory Turnover Ratio
Lowest at 1.9 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio






